Imcyse

Experts discuss future of clinical trial tech, focusing on AI's potential to enhance trial effectiveness, digital endpoints' ability to reduce trial timelines and subject numbers, tools like Placebell for improved statistical analysis, and AI's role in guiding trial design and patient selection.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

The 'Multiple Sclerosis - Pipeline Insight, 2024' report by ResearchAndMarkets.com covers 80+ companies and 85+ pipeline drugs, including IMU-838 (Immunic), Masitinib (AB Science), Foralumab (Tiziana Life Sciences), IMCY-0141 (ImCyse), and BMS-986353 (Bristol-Myers Squibb). It provides insights into clinical and nonclinical stage products, therapeutics assessment, and pipeline development activities.